News Daily News How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions Michael O'Riordan April 22, 2020
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Daily News COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients Todd Neale March 27, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Daily News Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease Michael O'Riordan March 13, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Conference News ISC 2020 Optimal Time to Start Anticoagulation After Stroke Remains Unclear Todd Neale February 27, 2020
News Conference News ISC 2020 Telehealth Program Helps Minority Stroke Survivors Control BP Todd Neale February 26, 2020
News Conference News ISC 2020 SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy Todd Neale February 25, 2020
News Conference News ISC 2020 Antihypertensive Treatment is Subpar After ICH Todd Neale February 19, 2020
News Daily News Trials of New Cancer Drugs Failing to Address Potential CV Risks Todd Neale February 10, 2020
News Daily News Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results Michael O'Riordan January 27, 2020
News Daily News Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use L.A. McKeown January 21, 2020
News Daily News Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication Michael O'Riordan January 17, 2020
News Daily News Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes Michael O'Riordan January 14, 2020
News Daily News FDA Approves Icosapent Ethyl for Reducing CVD Events Michael O'Riordan December 13, 2019